- Home
- ALDX vs PRQR Comparison
ALDX vs PRQR Comparison
Compare ALDX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- PRQR
- Stock Information
- Founded
- ALDX 2004
- PRQR 2012
- Country
- ALDX United States
- PRQR Netherlands
- Employees
- ALDX N/A
- PRQR N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- PRQR Health Care
- Exchange
- ALDX Nasdaq
- PRQR Nasdaq
- Market Cap
- ALDX 160.8M
- PRQR 179.1M
- IPO Year
- ALDX 2014
- PRQR 2014
- Fundamental
- Price
- ALDX $4.30
- PRQR $2.18
- Analyst Decision
- ALDX Strong Buy
- PRQR Strong Buy
- Analyst Count
- ALDX 2
- PRQR 8
- Target Price
- ALDX $9.50
- PRQR $8.88
- AVG Volume (30 Days)
- ALDX 1.0M
- PRQR 371.0K
- Earning Date
- ALDX 07-31-2025
- PRQR 08-07-2025
- Dividend Yield
- ALDX N/A
- PRQR N/A
- EPS Growth
- ALDX N/A
- PRQR N/A
- EPS
- ALDX N/A
- PRQR N/A
- Revenue
- ALDX N/A
- PRQR $21,212,711.00
- Revenue This Year
- ALDX N/A
- PRQR N/A
- Revenue Next Year
- ALDX N/A
- PRQR N/A
- P/E Ratio
- ALDX N/A
- PRQR N/A
- Revenue Growth
- ALDX N/A
- PRQR 85.91
- 52 Week Low
- ALDX $1.14
- PRQR $1.07
- 52 Week High
- ALDX $7.20
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ALDX 78.08
- PRQR 65.20
- Support Level
- ALDX $3.68
- PRQR $1.89
- Resistance Level
- ALDX $4.21
- PRQR $2.54
- Average True Range (ATR)
- ALDX 0.28
- PRQR 0.13
- MACD
- ALDX 0.10
- PRQR 0.01
- Stochastic Oscillator
- ALDX 93.48
- PRQR 39.85
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.